Congenital muscular dystrophy with laminin α2 chain-deficiency, also known as MDC1A, is a severe neuromuscular disorder for which there is no cure. Patients with complete laminin α2 chain-deficiency typically have an early onset disease with a more severe muscle phenotype while patients with residual laminin α2 chain expression usually have a milder disease course. /dy 2J animals. However, bortezomib neither improved histological hallmarks of disease nor increased muscle strength and locomotive activity in dy 2J /dy 2J mice. Altogether our data suggest that proteasome inhibition does not mitigate muscle dysfunction caused by partial laminin α2 chain-deficiency. Still, it is possible that proteasome inhibition could be useful as a supportive therapy in patients with complete absence of laminin α2 chain.
Introduction
Mutations in the LAMA2 gene, encoding the laminin α2 chain of the extracellular matrix protein laminin-211, leads to congenital muscular dystrophy type 1A (MDC1A), which is a life threatening disease. Genotype-phenotype analyses have demonstrated that complete deficiency of laminin α2 chain causes a more severe phenotype whereas partial absence leads to a milder disease course. The clinical manifestations of complete laminin α2 chain-deficiency include profound hypotonia at birth, widespread muscle weakness, proximal joint contractures, scoliosis, elevated serum creatine kinase levels and delayed motor milestones. Patients may achieve unsupported sitting but very few children acquire independent ambulation. Individuals with partial laminin α2 chain deficiency often have later onset of proximal muscle weakness and delayed motor milestones but achieve independent ambulation. Histologically, MDC1A skeletal muscle displays typical dystrophic characteristics with degenerating/regenerating and atrophic fibers, early inflammation and extensive connective tissue infiltration [1] [2] [3] [4] .
There are several mouse models for laminin α2 chain-deficiency that represent the clinical heterogeneity of MDC1A and phenocopy the skeletal muscle changes. The dy 3K /dy 3K mouse completely lacks laminin α2 chain and displays a very severe muscular dystrophy and peripheral neuropathy with a median survival of 22 to 23 days. The dy
2J
/dy 2J mouse model, on the other hand, has slightly reduced expression of a truncated laminin α2 chain that lacks the Nterminal domain involved in laminin polymerization. Consequently, dy
/dy 2J mice show a relatively mild muscular dystrophy (but with a severe peripheral neuropathy) and live more than six months [5] [6] [7] [8] . of disease, enhanced body weight, locomotion and survival and partially normalized miRNA expression and reduced the proteasome activity in human MDC1A myoblasts and myotubes [9, 10] . In order to evaluate if bortezomib also has beneficial effects in the mouse model of partial laminin α2 chain-deficiency we herein explored the use of bortezomib in dy 2J /dy 2J mice.
Quite unexpectedly, we found that bortezomib did not ameliorate any of the muscular dystrophy features in the dy 2J /dy 2J mouse model.
Materials and Methods

Transgenic Animals
Heterozygous dy 2J /dy 2J mice (B6.WK-Lama2dy-2J/J) were purchased from the Jackson Laboratory (Bar Harbor, ME) and bred and maintained in the animal facilities of the Biomedical Center at Lund University according to institutional animal care guidelines. Permission was given by the Malmö/Lund (Sweden) ethical committee for animal research (ethical permit numbers M152-14 and M180-14).
Bortezomib Treatment
Bortezomib was purchased from LC Laboratories (Woburn, MA). A stock solution was stored in -80°C (dissolved in dimethylsulfoxide) and further diluted in sterile sodium chloride before administration. Mice were either injected twice with approximately 0.4 mg/kg i.v. at 2.5 weeks of age and 0.3 mg/kg i.v. at 3.5 weeks of age, or injected altogether six times with approximately 0.4 mg/kg i.v. at 2.5 weeks of age; 0.3 mg/kg i.v. at 3.5 weeks of age; 0.2 mg/kg i.v. at 4.5 weeks of age; 0.2 mg/kg s.c. at 5.5 and 6.5 weeks of age and finally 0.16 mg/kg s.c. at 7.5 weeks of age. Mice were subsequently analyzed at 5.5 and 8.5 weeks of age, respectively. Quadriceps and triceps muscles were processed for immunofluorescence, morphometric analysis and hydroxyproline assay. Plasma was also collected for analysis of circulating miRNAs and creatine kinase activity. 
Histology and Immunofluorescence
Morphometric Analysis
Quantifications were performed on cross sections of entire quadriceps and triceps muscle. H&E and Masson's trichrome stained sections were scanned using an Aperio ScanScope CS2 scanner with ScanScope console version 8.2.0.1263 (Aperio, Vista, CA). For quantification of tenascin-C and CD11b labeling, we used multiple Tiff-format images at x 10 magnification covering the whole muscle. The area within muscle corresponding to Masson's trichrome-positive area and to tenascin-C and CD11b labeling was quantified relative to the entire area of the quadriceps and triceps cross section. Images were converted to 8-bit-mode images and the measurements were set to a threshold that was manually adjusted for every individual image (the total muscle area versus stained area, measured in square pixels). The images were analyzed using ImageJ software version 1.43u (NIH, Bethesda, MD). Central nucleation was also quantified using ImageJ. The fiber area of biotinylated WGA stained muscle fibers was measured and quantified using Adobe Photoshop CS5 extended version (Adobe Systems, San Jose, CA).
Hydroxyproline Assay
OCT blocks with quadriceps and triceps muscle were thawed and washed in PBS. The muscles were weighed and incubated overnight in 200 μl concentrated HCl (12 M) at 95°C. Twenty five μl of hydrolyzate was neutralized with 25 μl NaOH (6 M) and incubated with 450 μl chloramine-T reagent (0.056 M) at room temperature for 25 min. A volume of 500 μl freshly prepared Ehrlich's reagent [1 M 4-(dimethylamino)benzaldehyde] was added to each sample and incubated at 65°C for 1 h. After cooling on ice, 100 μl in duplicates was transferred to a 96-well plate and absorbance was read at 560 nm. Standards from 4-hydroxyproline at concentrations (μg/ml; 0, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0) were treated the same way as the samples. Absorbance (A 560 ) of standards was plotted against amount of hydroxyproline (μg) and a linear regression was performed to determine slope and intercept. All absorbance values were subtracted with blank (0μg/ml hydroxyproline). Content of hydroxyproline in samples was calculated by equation:
x ðmgÞ ¼ ðA 560 ÀY axisintercept Þ=slope
Collagen conversion factor = 13.5 [12, 13] . Values are presented as relative amount of collagen.
Exploratory Locomotion Test
Exploratory locomotion was evaluated in an open-field test. In each experiment, a mouse was placed into a new cage and allowed to explore the cage for 5 minutes. The time that the mouse spent moving around was measured, as well as number of stand-ups (on hindlimbs).
Grip Strength
Forelimb grip strength was measured on a grip-strength meter (Columbus Instruments, Columbus, OH) as previously described [14] . In short, the mouse was held by the base of the tail and allowed to grasp the flat wire mesh of the pull bar with its forepaws. When the mouse got a good grip it was slowly pulled away by its tail until it released the pull bar. Each mouse was allowed to pull the pull bar five times. The two lowest values were rejected and the mean of the three remaining values was counted. Animals were not subjected to any training prior to the experiment.
RNA Isolation from Plasma, cDNA Synthesis and qPCR for miRNA Detection
As previously described [12] , blood was collected from heart puncture and transferred to anticoagulant tubes (EDTA), which were centrifuged at 1100 x g for 10 min in 4°C. Total RNA from blood plasma was extracted using the manufacturer's (miRNeasy Serum/Plasma kit; Qiagen, Valencia, CA) instructions. Briefly, the samples were thawed on ice and then centrifuged at 3000 x g for 5 min in 4°C. Fifty μl plasma was transferred to a new microcentrifuge tube containing 190 μl of QIAzol mixture containing 0.8 μg/μl MS2 bacteriophage RNA (Roche Applied Science, Penzberg, Germany) and incubated for 5 min. Fifty μl of chloroform was added to each tube and incubated for 2 min followed by centrifugation at 12000 x g for 15 min in 4°C. The supernatant was transferred to a new microcentrifuge tube and 435 μl ethanol was added to each sample. The sample was transferred to a spin column, then a rinse step was performed with 1 x 700 μl RWT buffer, 1 x 500 μl RPE buffer and 1 x 500 μl 80% ethanol. Total RNA was eluted by adding 14 μl RNase-free water to the membrane followed by centrifugation at 12000 g for 1 min. The RNA was stored at -80°C. Two μl of eluted blood plasma RNA was reversed transcribe in a 15 μl reaction using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA). Two μl of cDNA was assayed in 20 μl PCR reaction according to the protocol for the TaqMan Fast Advanced Master Mix. The amplification was performed in 96-well plates in a LightCycler 480 qPCR system (Roche Diagnostics, Basel, Switzerland). The determination of C T (by the second-derivative method) was done using the manufacturer's LightCycler software. MiRNA levels were calculated relative to miR-122. Primers/Probes for miR-1, miR-133a and miR-122 were designed by Applied Biosystems (assay ID 002246, 002222 respectively 002245).
Creatine kinase assay
Blood was collected from heart puncture and transferred to anti-coagulant tubes (EDTA) and centrifuged at 1100 x g for 10 min at 4°C. Plasma was analyzed at Clinical Chemistry Laboratory at Skåne University Hospital. The CK_P_S Cobas method was used to quantify enzyme activity.
Statistical Analysis
Data were analyzed using the Kruskal-Wallis test with a Dunn's multiple comparison test to determine differences between groups followed Mann-Whitney U-test to determine the differences between two respective groups. Statistical significance was accepted for P < 0.05.
Results and Discussion
Two bortezomib injections do not reduce muscular dystrophy in dy 2J /dy 2J mice
In our previously published study, we demonstrated that dy 3K /dy 3K mice injected twice with bortezomib had higher body weight, were more active in an exploratory locomotion test, In order to analyze whether additional injections could be advantageous, we tested the following bortezomib injection regimen: three i.v. injections at 2.5, 3.5 and 4.5 weeks of age and three s.c. injections at 5.5, 6.5 and 7.5 weeks of age and final analysis at 8.5 weeks of age. We started with 0.4 mg/kg and then gradually decreased the dose to 0.16 mg/kg in order to avoid serious adverse effects of bortezomib. Still, it has been demonstrated that bortezomib significantly attenuates the severity of collagen-induced arthritis (another musculoskeletal disorder) in mice within this dose range [15] . Also, in several previous studies it has been demonstrated that bortezomib is taken up in skeletal muscle after intravenous injections in mice and rats [16] [17] [18] . One hindlimb (quadriceps femoris) and one forelimb (triceps brachii) muscle were chosen for histological analyses. We found that the muscle morphology of dy 2J /dy 2J muscle was not further improved by additional injections of bortezomib. Dystrophic changes such as fiber size variability, central nucleation and connective tissue infiltration were evident to a similar degree in quadriceps and triceps muscle of untreated and bortezomib-treated dy 2J /dy 2J mice (Fig 1) . In 8.5-week-old dy 2J /dy 2J animals, the quadriceps and triceps muscle fiber-size distribution was shifted to smaller diameters compared to wild-type muscles. However, bortezomib administration did not affect fiber size distribution in either dy 2J /dy 2J quadriceps or triceps muscle ( Figs   2A and 3A ). An increased number of muscle fibers with centrally located nuclei was also noticed in 8. /dy 2J quadriceps muscle. Data are expressed as means ± SEM. Number of mice analyzed is indicated in data bars. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. doi:10.1371/journal.pone.0146471.g002
Proteasome Inhibition in dy 2J /dy 2J Mice untreated wild-type male mice (Fig 4A) . In female wild-type mice, on the other hand, multiple injections of bortezomib did not cause any weight loss (data not shown). We have previously demonstrated that exploratory locomotion of dy 3K /dy 3K mice in an open field test is significantly reduced compared to wild-type animals [9, 10] . Similarly, dy 2J /dy 2J mice at the age of 8.5
weeks were also significantly less active (roughly 1.1-fold) compared to wild-type mice. /dy 2J triceps muscle. Data are expressed as means ± SEM. Number of mice analyzed is indicated in data bars. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Bortezomib did, however, not enhance the exploratory locomotion of dy 2J /dy 2J mice (Fig 4B) .
We also analyzed the average number of stand-ups over a 5-minute period and observed that 8.5-week-old dy 2J /dy 2J mice displayed a significant reduction (around 3-fold) in stand-up activity compared to wild-type mice. No increase in stand-up activity was noted upon bortezomib treatment (Fig 4C) . Subsequently, we measured the muscle strength of dy 2J /dy 2J and wild-type forelimbs using a grip-strength meter. Dy 2J /dy 2J mice were significantly weaker (approximately 2.3-fold) compared to control mice and bortezomib did not increase the grip strength (Fig 4D) . . Data are expressed as means ± SEM. Number of mice analyzed is indicated in data bars, except in panel F, in which n = 4. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Lastly, we measured plasma creatine kinase (CK) levels and the expression of two musclespecific miRNAs in plasma from 8.5-week-old animals in order to examine the sarcolemmal integrity of skeletal muscle fibers. A significant increase in CK levels was observed in dy 2J /dy 2J mice but bortezomib did not significantly lower the CK levels in the blood (Fig 4E) /dy 2J mice.
In conclusion, these findings do not support a putative role for bortezomib in the treatment of MDC1A with partial laminin α2 chain-deficiency. However, we would like to stress that proteasome inhibition (two injections of bortezomib) diminished the severity of muscle dysfunction in dy 3K /dy 3K mice [9, 10] but we have not yet evaluated the effects of multiple injections in dy 3K /dy 3K mice. Nevertheless, it is plausible that proteasome inhibition could be a useful supportive therapy in patients with complete deficiency of laminin α2 chain.
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